The Relative Strength (RS) Rating for Illumina headed into a new percentile Monday, as it got a lift from 68 to 74.
This exclusive rating from Investor's Business Daily identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the top-performing stocks tend to have an RS Rating north of 80 as they launch their largest climbs. See if Illumina can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Illumina has moved more than 5% past a 137.18 entry in a first-stage cup with handle, meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week line.
The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 13% to 245%. Revenue rose from -5% to -3%.
Illumina earns the No. 8 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Medpace Holdings are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
